GlassScriptPhysician profile
Gilanthony D Ungab
NPI 1528176641
$22,022.83
in general payments reported to CMS, 2019-2025
27 companies · $552 in 2025
The $552 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,648 · 2020: $6,663 · 2021: $8,482 · 2022: $374 · 2023: $1,767 · 2024: $538 · 2025: $552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,856.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,856.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $12,378.48 | 2019-2024 | Lifevest |
| Boston Scientific Corporation | $1,602.43 | 2019-2025 | Watchman Access System, General - Therapies |
| Cvrx, INC. | $1,279.77 | 2019-2023 | Barostim Neo System |
| Biotronik INC. | $799.34 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $726.23 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $643.75 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $628.31 | 2019-2021 | |
| Abbott Laboratories | $618.21 | 2019-2025 | Ensite |
| Philips North America LLC | $613.71 | 2023-2025 | Ambulatory Monitoring & Diagnostics Undivided, (5044) Mcot, (Ck4) Mcot |
| Genentech USA, INC. | $343.30 | 2019 | |
| Pfizer INC. | $308.26 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $305.00 | 2019-2024 | Xarelto |
| Kestra Medical Technology Services, INC. | $276.55 | 2023 | Assure Wcd |
| Elutia, INC. | $264.86 | 2019-2020 | |
| Medtronic Vascular, INC. | $239.71 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Respicardia, INC. | $205.48 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $149.94 | 2023 | |
| Acutus Medical, INC. | $126.81 | 2023 | |
| Bardy Diagnostics, INC. | $122.22 | 2020 | |
| Medtronic USA, INC. | $81.50 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $66.90 | 2019 | |
| Abiomed | $61.54 | 2022 | |
| Braemar Manufacturing, LLC | $61.34 | 2019 | |
| Glaxosmithkline, LLC. | $60.48 | 2019 | |
| Mylan Specialty L.P. | $20.75 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $19.86 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gilanthony Ungab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.